Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $9 from $7 and keeps a Buy rating on the shares after having hosted CFO Jeff Baker for investor meetings earlier this week. The firm came away from the meetings “feeling confident” in Paysign’s pharma pipeline, scalable operating model, and new plasma applications, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Paysign management to meet with Lake Street
- DA Davidson research director holds a bison roundup conference call
- 3 Best Stocks to Buy Now, 6/16/2025, According to Top Analysts
- Paysign price target raised to $8 from $7 at DA Davidson
- PaySign’s Strong Growth Potential and Strategic Positioning in Healthcare: A Buy Rating by Gary Prestopino